U.S. markets closed

Akero Therapeutics, Inc. (AKRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.06+1.17 (+3.91%)
At close: 4:00PM EST

Akero Therapeutics, Inc.

170 Harbor Way
3rd Floor
South San Francisco, CA 94080
United States
650 487 6488

Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew ChengPres, CEO & Director747.05kN/A1967
Dr. Jonathan M. YoungCo-Founder, EVP & COO600kN/A1970
Mr. Timothy RolphCo-Founder & Chief Scientific Officer600kN/A1954
Mr. William R. White J.D.Exec. VP, CFO & Head of Corp. Devel.494.3kN/A1973
Ms. Kitty YaleExec. VP & Chief Devel. OfficerN/AN/A1972
Mr. John J. SchembriVP of Fin. & ControllerN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Akero Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.